Homa Yeganegi, Vice President, Global Scientific and Medical Affairs

As the Global Program Leader for PEGPH20 (pegvorhyaluronidase alfa), Ms. Homa Yeganegi directs the commercialization strategy and operational planning for Halozyme’s investigational new drug, PEGPH20. As the program team lead, she is responsible for Halozyme resources from research to development to launch readiness for PEGPH20. She joined Halozyme in March 2016 as the Vice President of Global Medical and Scientific Affairs. Ms. Yeganegi has extensive experience in building and leading oncology-focused Global Medical Affairs teams at Clovis Oncology Pharmaceuticals, Exelixis Pharmaceuticals and Onyx Pharmaceuticals. Most recently she was Vice President of Global Medical Affairs at Clovis Oncology Pharmaceuticals where she successfully supported the pre-launch activities for Rociletinib in non-small cell lung cancer in the US and EU. She has a demonstrated track record of success driving strategic data generation, opinion leader development and engagement, scientific strategy and communication including global medical information and scientific education. Ms. Yeganegi has a B. Sc. in Biology from the University of Tehran, Iran, a Master of Science in Neuroanatomy from the University of Western Australia and is completing her Ph.D. in Health Sciences.


You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.